Table 3. Time-dependent survival analysis (overall survival) stratified according to tumour type with prediagnosis aspirin users.

			Overall survival
	No. at risk	No. events	Crude hazard ratio	95% CI	P-value	Adjusted hazard ratioa	95% CI	P-value
Aspirin users vs nonusers (n=12 109)
Nonusers	8366	4913	1 (Reference)			1 (Reference)
Pre and post-diagnosis aspirin usersb	2736	1647	0.69	0.64–0.75	<0.001	0.61	0.57–0.66	<0.001
Aspirin users vs nonusers per tumour type
Oesophageal cancer (n=1180)
Nonusers	894	741	1 (Reference)			1 (Reference)
Aspirin Usersb	286	229	0.64	0.52–0.79	<0.001	0.61	0.49–0.76	<0.001
Gastric cancer (n=933)
Nonusers	714	574	1 (Reference)			1 (Reference)
Aspirin Usersb	219	184	0.90	0.72–1.13	0.37	0.85	0.67–1.07	0.17
Pancreatic cancer (n=876)
Nonusers	681	648	1 (Reference)			1 (Reference)
Aspirin Usersb	195	183	0.68	0.54–0.84	<0.001	0.67	0.53–0.84	0.001
Hepatobiliary cancer (n=477)
Nonusers	364	317	1 (Reference)			1 (Reference)
Aspirin Usersb	113	101	0.81	0.61–1.08	0.16	0.69	0.51–0.93	0.02
Colon cancer (n=4730)
Nonusers	3469	1642	1 (Reference)			1 (Reference)
Aspirin Usersb	1261	612	0.67	0.59–0.76	<0.001	0.55	0.48–0.63	<0.001
Rectal cancer (n=2687)
Nonusers	2080	910	1 (Reference)			1 (Reference)
Aspirin Usersb	607	306	0.78	0.65–0.94	0.008	0.63	0.52–0.75	<0.001

Abbreviation: CI=confidence interval.

^aAdjusted for stage, sex, age at diagnosis, surgery, radiotherapy, chemotherapy and comorbidities.

^bOnly patients using aspirin both pre- and post diagnosis were analysed.